Bristol Myers therapy slows rare tumor progression, bolstering radiopharma push
BMY•Bristol Myers Squibb said its experimental therapy RYZ101 significantly delayed disease progression in a late-stage trial of patients with rare, advanced gastrointestinal and pancreatic tumors. The company did not disclose detailed results and plans to discuss the data with regulators.
1. Trial results
RYZ101 was tested against standard-of-care treatments in patients with gastroenteropancreatic neuroendocrine tumors whose disease had progressed after Lutetium-177-based therapy. Bristol Myers said the therapy’s safety profile was consistent with previous studies; trial participants will continue treatment and be followed to assess overall survival.
2. Radiopharmaceutical strategy
Bristol Myers added RYZ101 through its $4.1 billion takeover of RayzeBio. The therapy uses radioactive isotope actinium-225 to deliver radiation directly to tumor cells. The company plans to present the trial results at a future medical meeting and said RYZ101 is also being tested in earlier-stage trials for hormone receptor-positive metastatic breast cancer.
